PharmaTelevision - Biosceptre: A New Approach to Cancer Research

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Biosceptre: A New Approach to Cancer Research

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Alan Bootes, Chairman of Biosceptre International Ltd.

Filmed at AusBiotech 2009, they discuss:

• Biosceptre's unconventional approach to cancer
• the patents involved in Biosceptre's work
• partnering with other firms
• Alan's future hopes for Biosceptre's Biomarker

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Biosceptre's unconventional approach to cancer.

Fintan Walton:

Hello and welcome to Pharmatelevision news review here in Melbourne Australia. On this show I have Alan Bootes who is chairman of Biosceptre International Ltd based in Sydney Australia, welcome to the show.

Alan Bootes:

Thank you very much Fintan Walton.

Fintan Walton:

Biosceptre is a biotech company it's a privately held company, what sets Biosceptre apart from other companies in the biotech sector?

Alan Bootes:

We are in the immunological field looking at oncology solutions through immunological approaches that put us in with several hundred perhaps a thousand other small biotech's around the world. What sets Biosceptre apart is the is the approach we are taking, conventional wisdom and the path that most companies are following is based on the philosophy that every cancer is different and people are studying in great and greater detail the individual characteristics of like of each cancer type to understand how they differ from each other, then looking for a target and enter that target building antibodies and looking for diagnostics or treatment modalities that's the conventional approach. Biosceptre scientists stumbled upon something which has a potential to stand up whole concept of personalized medicine, targeted medicine on a tip. They have discovered a single cancer marker which is being this observed on every single type of cancer observed so far and that's some I think different sort of cancer so there are many others out there but the point is we have never looked yet at cancer tissue which has not exhibited this particular marker and the company has been engaged for the last eight to nine years in developing a range of antibodies which uniquely bind to that marker and not to any other types of marker or any other type of cells.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Alan Bootes

Chairman

Alan Bootes, Chairman of the Board Mr Alan Bootes recently retired after a 37 year career as a global manager with Pfizer Inc, the world's leading Pharmaceutical and Animal Health Products Company. Having built a reputation as an organization development and turnaround specialist through roles in Asia and Africa / Middle East, he subsequently led Pfizer country businesses in Taiwan, Canada (where he lifted annual sales from $50 million, #30 rank, to over $500 million and industry leader in 9 years) and lastly Japan, where in 5 years he took Pfizer from #10 to #1 rank in sales. Alan Bootes also served as Chairman of the pharmaceutical industry associations inTaiwan, Canadaand Japan, where he played a leading role in health policy development together with government officials and other stakeholders. He brings to the board valuable experience in leadership, organization development and international marketing, especially in the Asian region. He has completed his BEc (Ag) (Univ. New Eng).

Biosceptre

Biosceptre International is a public, unlisted biotechnology company based in Sydney, Australia that is developing and commercializing antibodies to address a wide range of applications in the diagnosis and treatment of cancer. Biosceptre's Vision is to make a significant contribution to the diagnosis and treatment of cancer worldwide and provide a significant return to their shareholders. This will be achieved through advancing development of various applications of their proprietary cancer marker / target to the point where they can be acquired and commercialized by major global pharmaceutical companies. P2X7 is a major cellular receptor responsible for normal programmed cell death. Biosceptre's technology is based on the fundamental discovery of a subtly changed non-functional form of P2X7nf-P2X7 that is found on cells of all solid tumors, but not on cells of normal tissues. Biosceptre has patents aroundP2X7 and nf-P2X7 as a diagnostic marker and therapeutic target in human and animal cancers. The Company has developed and continues to develop an inventory of antibodies and antibody constructs which specifically target the non-functional forms of theP2X7receptors which are found on the majority of all cancer types and have application in both therapeutic and diagnostic areas.